New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
12:56 EDTABBV, PRGOPerrigo confirms AB therapeutic equivalent rating for testosterone gel 1.0%
Perrigo Company (PRGO) announced that it has received an AB therapeutic equivalent rating from the U.S. Food and Drug Administration for its previously approved New Drug Application for testosterone gel 1.0%. FDA concluded that Perrigo's testosterone product is therapeutically equivalent to AndroGel 1% (ABBV) and can be substituted with the full expectation that it will produce the same clinical effect and safety profile as AndroGel 1% when used under the conditions specified in the labeling. Other companies that have submitted NDAs referencing AndroGel 1.0% have failed to achieve the AB rating.
News For PRGO;ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
08:00 EDTABBVAbbVie announces expiration of HSR waiting period for Pharmacyclics acquisition
AbbVie (ABBV) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for AbbVie's purchase of Pharmacyclics (PCYC) has expired today. The expiration satisfies the exchange offer condition with respect to the approvals and clearances required under antitrust laws. Assuming that the other customary exchange offer conditions are satisfied, including a minimum tender of at least a majority of outstanding Pharmacyclics shares, it is expected that the exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics will expire today at 5:00 p.m., New York City time, without any further extension.
May 21, 2015
08:04 EDTABBVAbbVie announces offer consideration for acquisition of Pharmacyclics
AbbVie (ABBV) announced the per share offer consideration amounts pursuant to its previously announced offer to acquire each outstanding share of common stock of Pharmacyclics (PCYC) for a mix of cash and AbbVie common stock, as described in the Registration Statement on Form S-4 filed with the SEC by AbbVie on March 23, 2015, as amended. The mixed consideration will consist of $152.25 in cash and 1.6639 shares of AbbVie common stock and, subject to proration, the all-stock consideration will consist of 3.9879 shares of AbbVie common stock.
07:58 EDTABBVDeutsche sees AbbVie shares getting to $80 over summer
Deutsche Bank sees pipeline readouts over the summer pushing shares of AbbVie to $80. The firm keeps a Buy rating on the stock with an $80 price target after meting with management.
07:37 EDTPRGO, ABBVPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 20, 2015
09:07 EDTABBVJohnson & Johnson says exploring eight new indications for Imbruvica
Imbruvica is jointly developed and commercialized by Pharmacyclics (PCYC) and Johnson & Johnson (JNJ) subsidiary Janssen Biotech. AbbVie (ABBV) is in the process of acquiring Pharmacyclics.
07:21 EDTABBVUBS to hold a conference
Subscribe for More Information
May 19, 2015
08:57 EDTABBVLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
06:08 EDTPRGOPerrigo CEO says would talk with Mylan, but at a higher price, Globes reports
Subscribe for More Information
May 18, 2015
12:07 EDTPRGOPerrigo: there is price point where would engage with Mylan, Bloomberg reports
Subscribe for More Information
May 15, 2015
16:46 EDTABBVAbbVie extends exchange offer to acquire Pharmacyclics
AbbVie (ABBV) announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics (PCYC) to 5 p.m., New York City time, on May 22. The depositary of the exchange offer has advised that, as of 4:00 p.m., New York City time, on May 15, a total of approximately 42,822,941 shares of Pharmacyclics common stock were validly tendered and not properly withdrawn in the exchange offer. All other terms and conditions of the exchange offer remain unchanged.
10:29 EDTABBVAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:45 EDTABBVAbbVie reports FDA orphan designation for Humira in treatment of HS
Subscribe for More Information
May 14, 2015
13:12 EDTABBVAbbVie granted orphan status for Humira
Subscribe for More Information
10:41 EDTABBVAnalysts upbeat on Amgen's Kyprolis after ASCO abstracts
Subscribe for More Information
09:09 EDTABBVBristol-Myers down 1.3% after release of ASCO abstracts
Subscribe for More Information
May 13, 2015
13:12 EDTABBVSen. Sanders urges VA to break patents on Gilead hepatitis C drugs
Subscribe for More Information
May 12, 2015
08:48 EDTPRGOPerrigo acquires Patheon's Mexican operations for $34M
Subscribe for More Information
May 11, 2015
11:53 EDTPRGOTeva rejected chance to acquire Perrigo a few months ago, Globes reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use